FDA to assess Teva's biologics application for Neutroval

02/2/2010 | Reuters

The FDA will evaluate Teva Pharmaceutical Industries' biologics-license application for XM02, a white blood cell booster and a follow-on version of Amgen's Neupogen, the company announced. In its filing, Teva stated that it plans to market the drug as Neutroval.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA